Zanidatamab in combination for untreated HER2-positive unresectable advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma [ID6672]

  • Awaiting development
  • GID-TA11878
  • Expected publication date: TBC

34425-Zanidatamab-with-Chemotherapy-with-or-without-Tislelizumab-for-Gastroesophageal-Adenocarcinoma-V1.0-SEPT2025-NON-CONF.pdf